These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

403 related items for PubMed ID: 30911897

  • 1. Decreases in Both the Seroprevalence of Serum Antibodies and Seroprotection against Japanese Encephalitis Virus among Vaccinated Children.
    Wang R, Xie L, Gao N, Fan D, Chen H, Wang P, Zhou H, An J.
    Virol Sin; 2019 Jun; 34(3):243-252. PubMed ID: 30911897
    [Abstract] [Full Text] [Related]

  • 2. Low population Japanese encephalitis virus (JEV) seroprevalence in Udayapur district, Nepal, three years after a JE vaccination programme: A case for further catch up campaigns?
    Turtle L, Brindle HE, Schluter WW, Faragher B, Rayamajhi A, Bohara R, Gurung S, Shakya G, Yoksan S, Dixit S, Rajbhandari R, Paudel B, Adhikari S, Solomon T, Griffiths MJ.
    PLoS Negl Trop Dis; 2019 Apr; 13(4):e0007269. PubMed ID: 30986252
    [Abstract] [Full Text] [Related]

  • 3. Sero-Molecular Epidemiology of Japanese Encephalitis in Zhejiang, an Eastern Province of China.
    Pan JR, Yan JY, Zhou JY, Tang XW, He HQ, Xie RH, Mao HY, Zhang YJ, Xie SY.
    PLoS Negl Trop Dis; 2016 Aug; 10(8):e0004936. PubMed ID: 27560360
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Immunogenicity of a Japanese encephalitis chimeric virus vaccine as a booster dose after primary vaccination with SA14-14-2 vaccine in Thai children.
    Janewongwirot P, Puthanakit T, Anugulruengkitt S, Jantarabenjakul W, Phasomsap C, Chumket S, Yoksan S, Pancharoen C.
    Vaccine; 2016 Oct 17; 34(44):5279-5283. PubMed ID: 27628323
    [Abstract] [Full Text] [Related]

  • 7. Modeling the long-term persistence of neutralizing antibody in children and toddlers after vaccination with live attenuated Japanese encephalitis chimeric virus vaccine.
    Bouckenooghe A, Bailleux F, Feroldi E.
    Hum Vaccin Immunother; 2019 Oct 17; 15(1):72-79. PubMed ID: 30230947
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Low Protective Efficacy of the Current Japanese Encephalitis Vaccine against the Emerging Genotype 5 Japanese Encephalitis Virus.
    Cao L, Fu S, Gao X, Li M, Cui S, Li X, Cao Y, Lei W, Lu Z, He Y, Wang H, Yan J, Gao GF, Liang G.
    PLoS Negl Trop Dis; 2016 May 17; 10(5):e0004686. PubMed ID: 27139722
    [Abstract] [Full Text] [Related]

  • 10. A randomized study of the immunogenicity and safety of Japanese encephalitis chimeric virus vaccine (JE-CV) in comparison with SA14-14-2 vaccine in children in the Republic of Korea.
    Kim DS, Houillon G, Jang GC, Cha SH, Choi SH, Lee J, Kim HM, Kim JH, Kang JH, Kim JH, Kim KH, Kim HS, Bang J, Naimi Z, Bosch-Castells V, Boaz M, Bouckenooghe A.
    Hum Vaccin Immunother; 2014 May 17; 10(9):2656-63. PubMed ID: 25483480
    [Abstract] [Full Text] [Related]

  • 11. Long-term immunogenicity of the SA14-14-2 Japanese encephalitis (JE) vaccine (CD.JEVAX®) booster following chimeric JE (IMOJEV®) vaccine priming in Thai children.
    Chotpitayasunondh T, Suntarattiwong P, Yoksan S.
    Hum Vaccin Immunother; 2024 Dec 31; 20(1):2407663. PubMed ID: 39353860
    [Abstract] [Full Text] [Related]

  • 12. Cross-protection elicited by primary and booster vaccinations against Japanese encephalitis: a two-year follow-up study.
    Erra EO, Askling HH, Yoksan S, Rombo L, Riutta J, Vene S, Lindquist L, Vapalahti O, Kantele A.
    Vaccine; 2013 Dec 17; 32(1):119-23. PubMed ID: 24176496
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Immunogenicity of live attenuated Japanese encephalitis SA 14-14-2 vaccine among Sri Lankan children with previous receipt of inactivated JE vaccine.
    Wijesinghe PR, Abeysinghe MRN, Yoksan S, Yao Y, Zhou B, Zhang L, Fleming JA, Marfin AA, Victor JC.
    Vaccine; 2016 Nov 21; 34(48):5923-5928. PubMed ID: 27773472
    [Abstract] [Full Text] [Related]

  • 18. Retention of neutralizing antibodies to Japanese encephalitis vaccine in age groups above fifteen years in Korea.
    Lee HJ, Choi H, Park KH, Jang Y, Hong YJ, Kim YB.
    Int J Infect Dis; 2020 Nov 21; 100():53-58. PubMed ID: 32829050
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [A large-scale study on the safety and epidemiological efficacy of Japanese encephalitis (JE) live vaccine (SA14-14-2) in the JE endemic areas].
    Zhou B, Jia L, Xu X.
    Zhonghua Liu Xing Bing Xue Za Zhi; 1999 Feb 21; 20(1):38-41. PubMed ID: 10682513
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.